Inactive Instrument

SciSparc Ltd. Stock OTC Markets





Sales 2022 1.35 Sales 2023 2.88 Capitalization 2.56M
Net income 2022 -2M Net income 2023 -5M EV / Sales 2022 1,145,812 x
Net cash position 2022 3.55M Net cash position 2023 5M EV / Sales 2023 -848,893 x
P/E ratio 2022
-1.33 x
P/E ratio 2023
-0.34 x
Employees 3
Yield 2022 *
Yield 2023
Free-Float 99.98%
More Fundamentals * Assessed data
Dynamic Chart
SciSparc Signs Non-Binding Letter of Intent to Spin Off Advanced Clinical Stage Pharmaceutical Portfolio MT
SciSparc Ltd. Secures Strategic Advantage with Grant of European Patent CI
SciSparc Ltd. signed a merger agreement to acquire remaining stake in Automax Motors Ltd. CI
Tranche Update on SciSparc Ltd.'s Equity Buyback Plan announced on July 7, 2022. CI
SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
SciSparc Ltd. Receives Another Patent, Strengthening its Core Technology in Canada CI
SciSparc Ltd. Announces Successfully Dosed the First Patient in Its SCI-210 Clinical Trial At the Soroka Medical Center for Pediatric Patients CI
Top Premarket Gainers MT
SciSparc Ltd. Announces Enrollment of First Patient for Its Clinical Trial for Children with Autism Spectrum Disorder CI
Scisparc Ltd. Granted Patent for Core Technology in Multiple Jurisdictions in Europe CI
SciSparc Ltd. Receives Canadian Patent for Opioids Reduction Use in Pain Management Technology CI
SciSparc Ltd. Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing CI
Clearmind Medicine Submits Three International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds MT
Clearmind Medicine Submits Three International Patent Applications for Next Generation Psychedelic-Based Compounds MT
Scisparc Initiates Autism Spectrum Disorder Study MT
More news
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
More about the company